Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Next Previous
Trial Profile

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Cyclophosphamide; Cyclophosphamide; Dexamethasone; Dexamethasone; Hyaluronidase
  • Indications Amyloid light-chain amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ANDROMEDA
  • Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 03 Mar 2023 Results of subgroup analysis assessing safety and efficacy of daratumumab plus bortezomib/cyclophosphamide/dexamethasone in Asian patients with newly diagnosed AL amyloidosis, published in the Annals of Hematology.
    • 01 Jun 2022 Results of an analysis assessed the patient-reported outcomes published in the American Journal of Hematology
    • 30 Dec 2021 Planned End Date changed from 2 Aug 2024 to 16 Aug 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top